Organovo Announces First Delivery of 3D Liver Tissue to Key Opinion Leader

Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today announced that it has performed its first 3D Liver tissue delivery.

The achievement marks the delivery of Organovo's 3D Liver tissue to a laboratory outside of the company to a key opinion leader (KOL) for experimentation, and marks the achievement of a milestone along the pathway to commercial launch of its 3D liver tissue product.  Organovo achieved the milestone ahead of its April 2014 target date.  Key opinion leaders are generally experts, in this case top research scientists, in a particular field whose opinions and publications will influence practice.  Organovo expects KOLs to make recommendations on improvements to the tissue before launch and to influence peers through their reporting of their research results at conferences and through peer reviewed publications.

Uroplasty Reports Record Quarterly Revenue

~ U.S. Urgent PC Sales Up 19% in Fiscal Third Quarter
~~ Total Sales Increase by 14% to $6.4 Million

Uroplasty, Inc. (UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported strong financial results for the fiscal 2014 third quarter ended December 31, 2013. 

Total revenues for the fiscal third quarter 2014 were $6.4 million, up 14% from the same quarter in the prior year. Sales of the Company's Urgent^® PC Neuromodulation System in the United States grew 19% to $3.2 million, as compared to $2.7 million in the third quarter of the prior year.  Sales of Macroplastique in the United States grew 11% to $1.5 million in the third quarter of fiscal 2014.  Total net sales outside of the U.S. grew 11% to $1.6 million.

LED Medical Inc. Announces Distribution Agreement with Patterson Dental

LED Medical Diagnostics Inc. ("LED Medical" or the "Company") (TSX VENTURE:LMD) (LEDIF) (LME.F) is pleased to announce that its wholly-owned U.S. subsidiary, LED Dental Inc. ("LED Dental"), has entered into a non-exclusive partnership with Patterson Dental for the distribution of the company's VELscope® Vx Enhanced Oral Assessment System and product line within the US and Canadian markets.

"We are pleased to welcome Patterson Dental as our newest U.S. distribution partner for the VELscope® Vx family of products," stated Dr. David Gane, CEO of LED Medical. "Patterson Dental is one of the most respected names in North America, with an exemplary reputation for providing innovative products and focusing on the success of its customers," added Dr. Gane.

TotipotentRX Corporation and ThermoGenesis Corp. Report Statistically Significant Phase Ib Clinical Trial Results in Critical Limb Ischemia

New 60 Minute Rapid Bedside Treatment Substantially Reduces Amputations in No-Option Patients

ThermoGenesis Corp. (KOOL) a cellular therapy medical device company and TotipotentRX Corporation, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular and orthopedic disease announce their co-sponsored Phase Ib clinical trial safety and efficacy results treating no-option patients suffering from critical limb ischemia with Totipotent's CLIRST (Critical Limb Ischemia Rapid Stem cell Therapy) treatment. The companies will host a joint conference call to review the study results in detail on Monday, January 27, 2014 at 2:00pm Pacific (5:00pm Eastern).